Literature DB >> 25745027

Dialysis Modalities and HDL Composition and Function.

Michael Holzer1, Gernot Schilcher2, Sanja Curcic1, Markus Trieb1, Senka Ljubojevic3, Tatjana Stojakovic4, Hubert Scharnagl4, Chantal M Kopecky5, Alexander R Rosenkranz2, Akos Heinemann1, Gunther Marsche6.   

Abstract

Lipid abnormalities may have an effect on clinical outcomes of patients on dialysis. Recent studies have indicated that HDL dysfunction is a hallmark of ESRD. In this study, we compared HDL composition and metrics of HDL functionality in patients undergoing hemodialysis (HD) or peritoneal dialysis (PD) with those in healthy controls. We detected a marked suppression of several metrics of HDL functionality in patients on HD or PD. Compositional analysis revealed that HDL from both dialysis groups shifted toward a more proinflammatory phenotype with profound alterations in the lipid moiety and protein composition. With regard to function, cholesterol efflux and anti-inflammatory and antiapoptotic functions seemed to be more severely suppressed in patients on HD, whereas HDL-associated paraoxonase activity was lowest in patients on PD. Quantification of enzyme activities involved in HDL metabolism suggested that HDL particle maturation and remodeling are altered in patients on HD or PD. In summary, our study provides mechanistic insights into the formation of dysfunctional HDL in patients with ESRD who are on HD or PD.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  cardiovascular disease; hemodialysis; lipids; peritoneal dialysis

Mesh:

Substances:

Year:  2015        PMID: 25745027      PMCID: PMC4552105          DOI: 10.1681/ASN.2014030309

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  60 in total

1.  Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease.

Authors:  Nosratola D Vaziri; Kaveh Navab; Pavan Gollapudi; Hamid Moradi; Madeleine V Pahl; Cyril H Barton; Alan M Fogelman; Mohamad Navab
Journal:  J Natl Med Assoc       Date:  2011-06       Impact factor: 1.798

2.  Uremia alters HDL composition and function.

Authors:  Michael Holzer; Ruth Birner-Gruenberger; Tatjana Stojakovic; Dalia El-Gamal; Veronika Binder; Christian Wadsack; Akos Heinemann; Gunther Marsche
Journal:  J Am Soc Nephrol       Date:  2011-07-29       Impact factor: 10.121

Review 3.  Inflammation alters HDL composition and function: implications for HDL-raising therapies.

Authors:  Gunther Marsche; Marcus D Saemann; Akos Heinemann; Michael Holzer
Journal:  Pharmacol Ther       Date:  2012-12-14       Impact factor: 12.310

Review 4.  Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.

Authors:  Kazuhiko Kotani; Satoshi Kimura; Alejandro Gugliucci
Journal:  J Physiol Biochem       Date:  2011-04-12       Impact factor: 4.158

5.  HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction.

Authors:  Stephen Zewinger; Thimoteus Speer; Marcus E Kleber; Hubert Scharnagl; Rainer Woitas; Philipp M Lepper; Karolin Pfahler; Sarah Seiler; Gunnar H Heine; Winfried März; Günther Silbernagel; Danilo Fliser
Journal:  J Am Soc Nephrol       Date:  2014-03-07       Impact factor: 10.121

6.  Rapid isolation of lipoproteins and assessment of their peroxidation by high-performance liquid chromatography postcolumn chemiluminescence.

Authors:  W Sattler; D Mohr; R Stocker
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

Review 7.  Metabolic consequences of peritoneal dialysis.

Authors:  John Burkart
Journal:  Semin Dial       Date:  2004 Nov-Dec       Impact factor: 3.455

Review 8.  Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities.

Authors:  Anatol Kontush; M John Chapman
Journal:  Curr Opin Lipidol       Date:  2010-08       Impact factor: 4.776

9.  Human plasma phospholipid transfer protein specific activity is correlated with HDL size: implications for lipoprotein physiology.

Authors:  Marian C Cheung; Gertrud Wolfbauer; Hiroshi Deguchi; José A Fernández; John H Griffin; John J Albers
Journal:  Biochim Biophys Acta       Date:  2008-12-30

10.  Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease.

Authors:  David J Kennedy; W H Wilson Tang; Yiying Fan; Yuping Wu; Shirley Mann; Michael Pepoy; Stanley L Hazen
Journal:  J Am Heart Assoc       Date:  2013-04-04       Impact factor: 5.501

View more
  35 in total

Review 1.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

2.  Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients.

Authors:  Yasunori Suematsu; Masaki Goto; Christina Park; Ane C F Nunes; WangHui Jing; Elani Streja; Connie M Rhee; Siobanth Cruz; Moti L Kashyap; Nosratola D Vaziri; Vasanthy Narayanaswami; Kamyar Kalantar-Zadeh; Hamid Moradi
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

3.  Kidney function is associated with an altered protein composition of high-density lipoprotein.

Authors:  Katya B Rubinow; Clark M Henderson; Cassianne Robinson-Cohen; Jonathan Himmelfarb; Ian H de Boer; Tomas Vaisar; Bryan Kestenbaum; Andrew N Hoofnagle
Journal:  Kidney Int       Date:  2017-07-26       Impact factor: 10.612

Review 4.  HDL in CKD-The Devil Is in the Detail.

Authors:  Florian Kronenberg
Journal:  J Am Soc Nephrol       Date:  2018-02-22       Impact factor: 10.121

Review 5.  Soy-based renoprotection.

Authors:  Nancy J McGraw; Elaine S Krul; Elizabeth Grunz-Borgmann; Alan R Parrish
Journal:  World J Nephrol       Date:  2016-05-06

Review 6.  ESRD-induced dyslipidemia-Should management of lipid disorders differ in dialysis patients?

Authors:  Hamid Moradi; Elani Streja; Nosratola D Vaziri
Journal:  Semin Dial       Date:  2018-04-29       Impact factor: 3.455

7.  CKD Increases Carbonylation of HDL and Is Associated with Impaired Antiaggregant Properties.

Authors:  Nans Florens; Catherine Calzada; Sandrine Lemoine; Marie Michèle Boulet; Nicolas Guillot; Christophe Barba; Julie Roux; Fréderic Delolme; Adeline Page; Jean Michel Poux; Maurice Laville; Philippe Moulin; Laurent Soulère; Fitsum Guebre-Egziabher; Laurent Juillard; Christophe O Soulage
Journal:  J Am Soc Nephrol       Date:  2020-06-09       Impact factor: 10.121

8.  Alteration of HDL Protein Composition with Hemodialysis Initiation.

Authors:  Ke Wang; Leila R Zelnick; Andrew N Hoofnagle; Tomas Vaisar; Clark M Henderson; Peter B Imrey; Cassianne Robinson-Cohen; Ian H de Boer; Yan-Ting Shiu; Jonathan Himmelfarb; Gerald J Beck; Bryan Kestenbaum
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-25       Impact factor: 8.237

Review 9.  Kidneys: key modulators of high-density lipoprotein levels and function.

Authors:  Haichun Yang; Agnes B Fogo; Valentina Kon
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-05       Impact factor: 2.894

Review 10.  Kidney as modulator and target of "good/bad" HDL.

Authors:  Jianyong Zhong; Haichun Yang; Valentina Kon
Journal:  Pediatr Nephrol       Date:  2018-10-05       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.